HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sherron Kell Selected Research

levodopa drug combination carbidopa (Nakom)

3/2018Effect of Concomitant Medications on the Safety and Efficacy of Extended-Release Carbidopa-Levodopa (IPX066) in Patients With Advanced Parkinson Disease: A Post Hoc Analysis.
2/2017Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease.
4/2015Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.
1/2015Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson's Disease: Experience in Clinical Trials.
12/2014Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients.
2/2014Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease.
4/2013Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Sherron Kell Research Topics

Disease

7Parkinson Disease (Parkinson's Disease)
03/2018 - 04/2013
3Dyskinesias (Dyskinesia)
03/2018 - 12/2014
3Nausea
02/2014 - 09/2006
2Sleep Initiation and Maintenance Disorders (Insomnia)
12/2014 - 04/2013
2Dizziness (Lightheadedness)
02/2014 - 09/2006
2Headache (Headaches)
02/2014 - 09/2006
2Visceral Pain
02/2013 - 09/2009
2Urge Urinary Incontinence (Urge Incontinence)
09/2006 - 04/2002
1Confusion (Bewilderment)
12/2014
1Pain (Aches)
09/2009
1Premature Ejaculation
09/2006
1Overactive Urinary Bladder (Overactive Bladder)
09/2006

Drug/Important Bio-Agent (IBA)

7levodopa drug combination carbidopa (Nakom)FDA LinkGeneric
03/2018 - 04/2013
4Levodopa (L Dopa)FDA LinkGeneric
02/2017 - 04/2013
2Opioid Analgesics (Opioids)IBA
02/2013 - 09/2009
2D- phenylalanyl- D- phenylalanyl- D- norleucyl- N- (4- pyridinylmethyl)- D-argininamideIBA
02/2013 - 09/2009
2Oxycodone (Oxycontin)FDA LinkGeneric
02/2013 - 09/2009
2oxybutynin (Tavor)FDA LinkGeneric
09/2006 - 04/2002
1Dopamine Agonists (Dopamine Agonist)IBA
03/2018
1Monoamine Oxidase (MAO)IBA
03/2018
1entacapone (Comtan)FDA Link
03/2018
1Amantadine (Aman)FDA LinkGeneric
03/2018
1Carbidopa (Lodosyn)FDA LinkGeneric
02/2017
1Delayed-Action PreparationsIBA
04/2013
1Analgesics (Analgesic Drugs)IBA
09/2009
1kappa Opioid Receptors (kappa Opioid Receptor)IBA
09/2009
1dapoxetineIBA
09/2006
1Cholinergic Antagonists (Anticholinergics)IBA
09/2006
1Tolterodine Tartrate (Detrol)FDA Link
09/2006
1Muscarinic AntagonistsIBA
04/2002